ARC Submits Guidance on Drug Development in AL Amyloidosis to FDA
The Amyloidosis Research Consortium (ARC) submitted a draft guidance for industry on developing drugs for AL amyloidosis to the Food and Drug Administration (FDA), to improve the design of clinical trials and accelerate the review of potential therapies. Patients with...
Dale Schenk was born May 10, 1957 in Glendora, California to Walter Bernard Schenk, a firefighter, and Rosemary Schenk, a family therapist. He received an undergraduate degree in biology in 1979 from the University of California at San Diego, where...
On September 22nd and 23rd two members of the Amyloidosis Research Consortium were invited speakers at the Global Genes 5th Annual RARE Patient Advocacy Summit event in Huntington Beach, California. ARC CEO Isabelle Lousada delivered a presentation on The Patient's Role in...
ARC is supporting a Satellite Symposium at the Heart Failure Society of America (HFSA) Meeting, 4-6pm, September 17, 2016. Cardiologists miss the diagnosis of amyloidosis more frequently than any other discipline. Don't be one of them. Join ARC for an...
Amyloidosis Research Consortium Announces Publication of Seminal Manuscript in Peer-Reviewed Journal Leukemia Encouraging Use of NT-proBNP as Endpoint in Clinical Trials. International AL amyloidosis expert community agrees N-terminal pro-brain natriuretic peptide (NT-proBNP) is analytically validated and clinically qualified to be...
Join our email list to stay up to date on the latest Amyloidosis news.
To wrap up 2024, this month’s ARC Talks Webinar consisted of a conversation with ARC staff. We shared highlights from 2024, started to look ahead to 2025, and answered your questions about the work we do for the amyloidosis community.
The webinar concluded with a Q and A session.
Original Presentation Date:
December 18, 2024
0:00 — Intro
2:01 — Shaping ARC’s Purpose
5:03 — Research Overview
7:28 — The Amyloidosis Forum
9:23 — Healthcare Professional Survey
10:40 — Amyloidosis Community Survey
14:00 — CASE: Community and Stakeholder Engagement Overview
17:09 — Patient Support & Patient Programs
20:05 — Healthcare Provider Programs
23:54 — My Amyloidosis Pathfinder (MAP)
26:44 — ASPIRE: Amyloidosis Stakeholder Partnerships for Impact, Reach and Equity
31:29 — Development & Communications Overview
35:51 — Communications Highlights
38:36 — Development Highlights
40:48 — Q&A Session
41:43 — How do I stay informed about amyloidosis clinical trials?
43:43 — What can do if I’m too well for a clinical trial?
47:03 — What can be done for rarer types of amyloidosis?
50:36 — How does ARC engage with healthcare clinics and treatment centers?
52:48 — How does ARC impact rare diseaes public policy?
54:24 — How can people help ARC and the amyloidosis community?